Claims for Patent: 10,548,889

Summary for Patent: 10,548,889

Title:	Compositions of CXCR4 inhibitors and methods of preparation and use
Abstract:	The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
Inventor(s):	Karel Marie Joseph Brands
Assignee:	X4 Pharmaceuticals Inc
Application Number:	US16/215,963
Patent Claims:	1. An X4P-001 composition comprising a compound of formula I: or a pharmaceutically acceptable salt thereof; and at least one of the following compounds: or a pharmaceutically acceptable salt thereof, in an amount of about 0.01 to about 0.3% w/w of the X4P-001 composition; or a pharmaceutically acceptable salt thereof, in an amount of about 0.01 to about 0.4% w/w of the X4P-001 composition; or a pharmaceutically acceptable salt thereof, in an amount of about 0.01 to about 0.4% w/w of the X4P-001 composition; or a pharmaceutically acceptable salt thereof, in an amount of about 0.01 to about 0.4% w/w of the X4P-001 composition; or or a pharmaceutically acceptable salt thereof, in an amount of about 0.01 to about 0.25% w/w of the X4P-001 composition; and wherein the X4P-001 composition does not include the following compound in a detectable amount: or a pharmaceutically acceptable salt thereof. 2. The X4P-001 composition of claim 1, wherein the X4P-001 composition comprises each of I-2, I-3, I-5, I-6, and I-7; or a pharmaceutically acceptable salt thereof. 3. The X4P-001 composition of claim 2, wherein the composition further comprises I-1, or a pharmaceutically acceptable salt thereof, in an amount of about 0.01 to about 0.7% w/w of the X4P-001 composition. 4. The X4P-001 composition of claim 1, wherein the amount of I-2, or a pharmaceutically acceptable salt thereof, is from about 0.01 to about 0.2% w/w of the X4P-001 composition. 5. The X4P-001 composition of claim 4, wherein the amount of I-3, or a pharmaceutically acceptable salt thereof, is from about 0.01 to about 0.2% w/w of the X4P-001 composition. 6. The X4P-001 composition of claim 5, wherein the amount of I-5, or a pharmaceutically acceptable salt thereof, is from about 0.01 to about 0.2% w/w of the X4P-001 composition. 7. The X4P-001 composition of claim 6, wherein the amount of I-6, or a pharmaceutically acceptable salt thereof, is from about 0.01 to about 0.2% w/w of the X4P-001 composition. 8. The X4P-001 composition of claim 7, wherein the amount of I-7, or a pharmaceutically acceptable salt thereof, is from about 0.01 to about 0.2% w/w of the X4P-001 composition. 9. The X4P-001 composition of claim 3, wherein the amount of I-1, or a pharmaceutically acceptable salt thereof, is from about 0.02 to about 0.5% w/w of the X4P-001 composition. 10. The X4P-001 composition of claim 1, wherein the composition comprises at least two compounds selected from: I-2, or a pharmaceutically acceptable salt thereof, I-3, or a pharmaceutically acceptable salt thereof, I-5, or a pharmaceutically acceptable salt thereof, I-6, or a pharmaceutically acceptable salt thereof, or I-7, or a pharmaceutically acceptable salt thereof. 11. The X4P-001 composition of claim 1, wherein the composition comprises at least three compounds selected from: I-2, or a pharmaceutically acceptable salt thereof, I-3, or a pharmaceutically acceptable salt thereof, I-5, or a pharmaceutically acceptable salt thereof, I-6, or a pharmaceutically acceptable salt thereof, or I-7, or a pharmaceutically acceptable salt thereof. 12. The X4P-001 composition of claim 1, wherein the composition comprises at least four compounds selected from: I-2, or a pharmaceutically acceptable salt thereof, I-3, or a pharmaceutically acceptable salt thereof, I-5, or a pharmaceutically acceptable salt thereof, I-6, or a pharmaceutically acceptable salt thereof, or I-7, or a pharmaceutically acceptable salt thereof.